Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15969071 | 0.87 | ACACB (0.44) | ACACB | |
| SCHEMBL15968412 | 0.84 | ACACB (0.43) | ACACB | |
| SCHEMBL16213729 | 0.76 | CHRNB2 (0.50) | ACACB | |
| SCHEMBL17160932 | 0.75 | ALDH1A1 (0.47) | UBE2NNPC1ALDH1A1TP53MAPT | |
| SCHEMBL6489323 | 0.75 | GABRA1 (0.49) | UBE2NNPC1ALDH1A1TP53MAPT | |
| SCHEMBL18394836 | 0.73 | NPC1 (0.49) | UBE2NNPC1ALDH1A1TP53MAPT | |
| SCHEMBL15968378 | 0.73 | ACACB (0.46) | ACACB | |
| SCHEMBL17173720 | 0.72 | MAPT (0.51) | UBE2NNPC1ALDH1A1TP53MAPT | |
| SCHEMBL6492223 | 0.72 | MAPT (0.51) | UBE2NNPC1ALDH1A1TP53MAPT | |
| SCHEMBL15351663 | 0.71 | CYP2C9 (0.51) | NPC1ALDH1A1TP53MAPTXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | ACACB 1112/4885UBE2N 3093/4885NPC1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.